Switzerland stands as a global paragon of pharmaceutical excellence, contributing over 5% to the national GDP. From the Basel-City life sciences cluster to the "Health Valley" in the Leman region, the country is home to industry titans like Roche and Novartis, as well as over 2,500 biotech SMEs. For international stakeholders seeking Vaccines & Biologicals Service & Products in Switzerland, the landscape is defined by rigorous quality standards (Swissmedic), cutting-edge R&D, and a sophisticated cold-chain logistics network.
The Swiss market is currently transitioning towards "Biotech 4.0," integrating AI-driven drug discovery and personalized immunotherapy. The demand for biological products has surged, particularly for mRNA-based platforms and high-purity biological extracts. Switzerland's strategic position in the heart of Europe makes it a critical hub for vaccine distribution, ensuring that biological agents reach global markets with zero loss in efficacy. Our partnership models focus on bridging the high-tech Swiss regulatory environment with cost-efficient, high-capacity manufacturing hubs in China.
The roadmap for biologicals in Switzerland focuses on three core pillars:
By 2030, we anticipate Switzerland will lead the world in decentralized vaccine production, where biological reagents are stored and formulated locally to respond to regional health crises instantly.
Jiangxi Serum Pharma Industries Co., Ltd. embodies the "China Factory 4.0" initiative. By integrating IoT sensors, automated clean-room monitoring, and blockchain-based batch tracking, we provide Swiss and global enterprises with a level of supply chain transparency previously unattainable. Our annual sales exceeding $10M USD are a testament to our ability to meet high-volume demands without compromising on the meticulous quality expected in the Swiss market.
Founded with Innovation DNA
Global Strategic Clients
Fully Certified Facilities
Meeting Swissmedic, EMA, and FDA standards through rigorous multi-stage auditing and GPM/BP/USP compliance.
End-to-end temperature-controlled logistics, ensuring biological integrity from our factory to Switzerland's medical centers.
Custom formulation services for Bio-Fermentation, Co-Crystallization, and Pre-Mix solutions tailored to Swiss research needs.
We provide more than just products; we provide a bridge between advanced biopharmaceutical research and scalable manufacturing reality.
Send Inquiry NowThe recent 50-day rapid FDA approval of Lilly’s oral GLP1 weight-loss drug marks a shift in how biological molecules are delivered. This breakthrough has accelerated the demand for high-purity raw materials and intermediates in the Swiss biotech corridor, where we are actively supporting partners in scaling production.
Learn More →Plant-derived Squalene is becoming a critical adjuvant in modern vaccine formulation. In Switzerland, where environmental sustainability is a regulatory priority, our high-purity plant extracts offer a ethical alternative to shark-derived components.
Learn More →We utilize validated cold-chain systems with real-time temperature monitoring. Each shipment of Vaccines & Biologicals includes a data logger to ensure that products remained within the specified range (e.g., 2°C to 8°C) throughout the entire transit from our facility to Swiss ports of entry.
Yes, our manufacturing partners are GMP certified, and we provide comprehensive documentation (CoA, MSDS, Stability Data) that aligns with the requirements of European and Swiss regulatory bodies. We have extensive experience in the export of Western medicines and biological raw materials to highly regulated markets.
Absolutely. We specialize in the customization of Pre-Mix, Co-Crystallization, and Bio-Fermentation. Our R&D team works closely with clients to develop specific biological profiles required for clinical trials or specialized pharmaceutical applications in the Swiss biotech cluster.
Standard pharmaceutical orders typically have a lead time of 15-30 days, while specialized biological products requiring custom fermentation may take 45-60 days. We prioritize supply chain resilience to ensure that Switzerland's healthcare providers have consistent access to life-saving products.
Leveraging 10 years of export expertise to serve the precision-driven Swiss market.
Contact Our Global Trade Specialists
